MEDNAX (MD) Given a $50.00 Price Target by Jefferies Group Analysts
Jefferies Group set a $50.00 target price on MEDNAX (NYSE:MD) in a research report report published on Tuesday morning. The firm currently has a hold rating on the stock. Jefferies Group also issued estimates for MEDNAX’s Q1 2018 earnings at $0.80 EPS, Q2 2018 earnings at $1.02 EPS, Q3 2018 earnings at $1.06 EPS, Q4 2018 earnings at $1.03 EPS and FY2018 earnings at $3.92 EPS.
MD has been the topic of a number of other research reports. Piper Jaffray Companies initiated coverage on MEDNAX in a research note on Wednesday, December 13th. They set an overweight rating and a $58.00 price objective on the stock. KeyCorp set a $51.00 price objective on MEDNAX and gave the stock a buy rating in a research note on Wednesday, November 1st. BMO Capital Markets initiated coverage on MEDNAX in a research note on Monday, October 16th. They set a market perform rating and a $46.00 price objective on the stock. SunTrust Banks set a $55.00 price objective on MEDNAX and gave the stock a hold rating in a research note on Thursday, December 21st. Finally, Robert W. Baird upped their price objective on MEDNAX from $47.00 to $48.00 and gave the stock a neutral rating in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company. MEDNAX currently has a consensus rating of Hold and a consensus price target of $54.75.
Shares of MEDNAX (MD) opened at $53.94 on Tuesday. The company has a market capitalization of $4,920.00, a P/E ratio of 15.68, a price-to-earnings-growth ratio of 1.40 and a beta of 0.31. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. MEDNAX has a 12 month low of $40.56 and a 12 month high of $72.13.
In other news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now owns 35,569 shares in the company, valued at approximately $1,834,649.02. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.
Several hedge funds have recently bought and sold shares of the stock. Thompson Siegel & Walmsley LLC increased its holdings in shares of MEDNAX by 19.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock worth $112,065,000 after acquiring an additional 428,184 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of MEDNAX by 4.8% during the 3rd quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock worth $100,198,000 after acquiring an additional 106,883 shares during the last quarter. Earnest Partners LLC increased its holdings in shares of MEDNAX by 0.7% during the 3rd quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock worth $64,437,000 after acquiring an additional 11,037 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of MEDNAX by 25.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,424,574 shares of the company’s stock worth $61,428,000 after acquiring an additional 293,011 shares during the last quarter. Finally, Sterling Capital Management LLC increased its holdings in shares of MEDNAX by 2.4% during the 2nd quarter. Sterling Capital Management LLC now owns 1,048,652 shares of the company’s stock worth $63,307,000 after acquiring an additional 24,228 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “MEDNAX (MD) Given a $50.00 Price Target by Jefferies Group Analysts” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/10/mednax-md-given-a-50-00-price-target-by-jefferies-group-analysts.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.